The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded a small business innovation research (SBIR) Phase I grant to Numerate to boost new drug programme for cardiac arrhythmias.
US-based biotechnology company Numerate has entered a multi-year agreement with Japan's Takeda Pharmaceutical Company to identify and deliver multiple clinical candidates.